Foghorn Therapeutics Inc (FHTX)
7.84
+0.12
(+1.55%)
USD |
NASDAQ |
Nov 22, 16:00
7.84
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Enterprise Value: 168.45M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 168.45M |
| November 21, 2024 | 161.78M |
| November 20, 2024 | 169.56M |
| November 19, 2024 | 166.23M |
| November 18, 2024 | 161.23M |
| November 15, 2024 | 177.90M |
| November 14, 2024 | 221.82M |
| November 13, 2024 | 224.60M |
| November 12, 2024 | 225.16M |
| November 11, 2024 | 248.51M |
| November 08, 2024 | 252.40M |
| November 07, 2024 | 239.06M |
| November 06, 2024 | 246.28M |
| November 05, 2024 | 229.61M |
| November 04, 2024 | 190.69M |
| November 01, 2024 | 194.03M |
| October 31, 2024 | 156.22M |
| October 30, 2024 | 179.57M |
| October 29, 2024 | 186.80M |
| October 28, 2024 | 183.46M |
| October 25, 2024 | 161.78M |
| October 24, 2024 | 157.33M |
| October 23, 2024 | 156.22M |
| October 22, 2024 | 152.33M |
| October 21, 2024 | 134.54M |
| Date | Value |
|---|---|
| October 18, 2024 | 159.00M |
| October 17, 2024 | 162.89M |
| October 16, 2024 | 183.46M |
| October 15, 2024 | 157.33M |
| October 14, 2024 | 145.66M |
| October 11, 2024 | 156.78M |
| October 10, 2024 | 125.09M |
| October 09, 2024 | 136.21M |
| October 08, 2024 | 155.11M |
| October 07, 2024 | 165.12M |
| October 04, 2024 | 167.90M |
| October 03, 2024 | 148.44M |
| October 02, 2024 | 195.69M |
| October 01, 2024 | 214.60M |
| September 30, 2024 | 250.17M |
| September 27, 2024 | 232.70M |
| September 26, 2024 | 250.40M |
| September 25, 2024 | 221.08M |
| September 24, 2024 | 243.77M |
| September 23, 2024 | 230.49M |
| September 20, 2024 | 267.56M |
| September 19, 2024 | 249.85M |
| September 18, 2024 | 243.77M |
| September 17, 2024 | 259.26M |
| September 16, 2024 | 227.17M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-150.99M
Minimum
Mar 22 2023
891.66M
Maximum
Dec 18 2020
163.95M
Average
110.87M
Median
Aug 09 2023
Enterprise Value Benchmarks
| Sana Biotechnology Inc | 383.72M |
| Omega Therapeutics Inc | 28.73M |
| Moderna Inc | 8.953B |
| United Therapeutics Corp | 13.72B |
| CEL-SCI Corp | 36.25M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.12M |
| Revenue (Quarterly) | 7.808M |
| Total Expenses (Quarterly) | 31.66M |
| EPS Diluted (Quarterly) | -0.31 |
| Profit Margin (Quarterly) | -244.9% |
| Earnings Yield | -24.49% |
| Normalized Earnings Yield | -23.90 |